Treatment of Mycobacterium avium Complex Pulmonary Disease
The pathogen Mycobacterium avium complex (MAC) is the most common cause of nontuberculous mycobacterial pulmonary disease worldwide. The decision to initiate long-term antibiotic treatment is difficult for the physician due to inconsistent disease progression and adverse effects associated with the...
Main Authors: | Yong-Soo Kwon, M.D., Won-Jung Koh, M.D., Charles L. Daley, M.D. |
---|---|
Format: | Article |
Language: | English |
Published: |
The Korean Academy of Tuberculosis and Respiratory Diseases
2019-01-01
|
Series: | Tuberculosis and Respiratory Diseases |
Subjects: | |
Online Access: | https://www.e-trd.org/search.php?where=aview&id=10.4046/trd.2018.0060&code=0003TRD&vmode=FULL |
Similar Items
-
A case of isolated pulmonary Mycobacterium avium complex infection in an immunocompetent host
by: Sivanthi Sapna Rajendran, et al.
Published: (2023-01-01) -
Risk factors for clinical progression in patients with pulmonary Mycobacterium avium complex disease without culture-positive sputum: a single-center, retrospective study
by: Mizu Nonaka, et al.
Published: (2023-06-01) -
Prescribing Patterns for Treatment of Mycobacterium avium Complex and M. xenopi Pulmonary Disease in Ontario, Canada, 2001–2013
by: Sarah K. Brode, et al.
Published: (2019-07-01) -
Antimicrobial susceptibility of Mycobacterium avium complex mycobacteria isolated from patients in Ural Federal District of the Russian Federation
by: Umpeleva T.V., et al.
Published: (2022-06-01) -
Effect of coexisting advanced extrapulmonary solid cancer on progression of Mycobacterium avium complex lung disease
by: Rei Inoue, et al.